So steroid-resistant graft-versus-host disease remains a big issue. First-line treatment remains based on steroids and we are not able to improve so far the first-line treatment, so we still have to struggle with this case of patients that are resistant to steroids.
Now we have ruxolitinib that is approved for the treatment of steroid-resistant patients, so we use ruxolitinib in most patients, except a few of them that may have some very important or very severe cytopenia when we can’t use it...
So steroid-resistant graft-versus-host disease remains a big issue. First-line treatment remains based on steroids and we are not able to improve so far the first-line treatment, so we still have to struggle with this case of patients that are resistant to steroids.
Now we have ruxolitinib that is approved for the treatment of steroid-resistant patients, so we use ruxolitinib in most patients, except a few of them that may have some very important or very severe cytopenia when we can’t use it. And for these patients or for patients that are resistant to ruxolitinib, things become more difficult. But we have some promising treatments that are on the way. We have the mesenchymal stem cell that gives some promising results to treat some patients that fail ruxolitinib, and we also have fecal microbiota transfer that shows some very promising results, in particular for the patients that have some GI involvement with acute graft-versus-host disease.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
